MDT-AP-2102
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- S2
- umap1_2d
- -0.42264155
- umap2_2d
- -9.225565114
- umap1_3d
- -3.418722002
- umap2_3d
- -1.352790645
- umap3_3d
- 5.153523796
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.480
- ALLOGRAFT_REJECTION+0.430
- E2F_TARGETS+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- MYC_TARGETS_V1+0.370
- G2M_CHECKPOINT+0.280
- INFLAMMATORY_RESPONSE+0.280
- UV_RESPONSE_DN+0.280
- COMPLEMENT+0.250
Top 10 suppressed
- HEME_METABOLISM-0.200
- TGF_BETA_SIGNALING-0.170
- MITOTIC_SPINDLE-0.120
- WNT_BETA_CATENIN_SIGNALING-0.060
- SPERMATOGENESIS-0.030
- PI3K_AKT_MTOR_SIGNALING-0.020
- PEROXISOME-0.010
- UV_RESPONSE_UP+0.000
- DNA_REPAIR+0.020
- ADIPOGENESIS+0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2390 | Med | Medulloblastoma | 0.869 |
| 2 | MDT-AP-0348 | Med | Medulloblastoma | 0.857 |
| 3 | MDT-AP-0118 | Med | Medulloblastoma | 0.852 |
| 4 | MDT-AP-0826 | Med | Medulloblastoma | 0.850 |
| 5 | MDT-AP-1196 | Med | Medulloblastoma | 0.847 |
| 6 | MDT-AP-1133 | Med | Medulloblastoma | 0.845 |
| 7 | MDT-AP-1374 | Med | Medulloblastoma | 0.845 |
| 8 | MDT-AP-3067 | Med | Medulloblastoma | 0.844 |
| 9 | MDT-AP-2865 | Med | Medulloblastoma | 0.843 |
| 10 | MDT-AP-0539 | Med | Medulloblastoma | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |